Glenmark Pharmaceuticals has informed that the Board of Directors of at its meeting held on May 28, 2021, which commenced at 05.30 pm and concluded at 09:55 pm, considered and approved the following: Audited Financial Results for the year ended March 31, 2021. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has enclosed the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com and Recommended Dividend @ 250% Rs 2.50 per share (face value of Re 1 each) on the Equity Share Capital of the Company for the financial year 2020-21 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
The above information is a part of company’s filings submitted to BSE.
